Meeting Psychosocial Needs to Improve Health: A Prospective Cohort Study

CURRENT STATUS: Under Review

Austyn Snowden, Jenny Young, Jan Savinc

Austyn Snowden
Edinburgh Napier University

Jenny Young
Edinburgh Napier University

✉️ J.Young3@napier.ac.uk Corresponding Author
ORCID: https://orcid.org/0000-0002-1588-2590

Jan Savinc
Edinburgh Napier University

Keywords

Holistic Needs Assessment, health status, EQ-5D, quality of life, community,
cancer, support, psychosocial
Abstract

Background Optimal cancer care has moved away from a disease-centric focus to a more holistic approach in order to proactively support people with their individual needs and concerns. While international policy clearly advocates this agenda, implementation into routine care is limited. Therefore, relevant interventions that measurably improve patient outcomes are essential to understand if this ideal is to become routine multidisciplinary practice. The aim of this study was to analyse the impact of a proactive, holistic, community-based intervention on health-related quality of life in a cohort of people diagnosed with cancer. Secondary aim was to explore the relationship between changes in health status and: cancer type, cancer stage, number of concerns expressed and change in severity of concerns pre and post intervention.

Method Prospective observational cohort study. A convenience sample of 437 individuals were referred to the service ‘Improving the Cancer Journey (ICJ) in the UK. Each completed the Euroqol EQ-5D-3L and visual analogue scale (VAS) and a Holistic Needs Assessment (HNA) during initial visit to the service and again at follow-up review, median 84 days later. Change between scores was tested with paired t-tests and relationships between variables with multiple regression models with heteroscedasticity-consistent standard errors.

Results Participants were White British with median age between 50-64 years. Cancer type and stage were varied. EQ-5D utility scores improved at follow-up by 0.121 [0.0891-0.153], p<.001, and VAS scores improved by 7.81 [5.88-9.74], p<.001. The strongest predictor of change was a decrease in severity of concerns. Cancer stage ‘palliative care’ contributed to a reduction in health status.

Conclusion This study is the first to show that a holistic community intervention dedicated to supporting the individual concerns of participants had both a statistically significant and clinically meaningful impact on participants’ health-related quality of life. The mean change in EQ-5D scores was more than the ‘minimally important clinical difference’ described in the literature. This is important because while quality of life has multiple determinants, this study has shown for the first time that it is possible to capture a clinically meaningful improvement as a function of reducing someone’s personally identified concerns.

Background

Globally, following a cancer diagnosis people report a wide range of needs and concerns [1]. The ideal of modern health and social care is therefore to optimise the skills available from a matching range of multidisciplinary professionals to meet these physical, psychological, social, emotional, financial, practical and spiritual needs, whilst at all times keeping the individual at the centre of decisions [2].

However, evidencing the benefits of holistic approaches to the patient is complex, not least because there are numerous interacting factors that impact on outcomes. For instance, there are different approaches to providing holistic care, including different assessment tools and assessor actions that affect the patient experience [3][4]. Even using the same assessment, individuals respond in different ways according to the professional undertaking the assessment [5], suggesting that there is no such thing as a ‘value free’ assessment of holistic need. Consequently, while policy has recognised the importance of routine, person-centred, psychosocial care [6], concerns relating to implementation barriers, the lack of clarity on the best way to identify needs and poor evidence of impact prevents widespread uptake [7][8]. Nevertheless, successful interventions exist. Therefore, the most appropriate learning at present comes from successful examples of care delivery consistent with this holistic agenda.

The intervention – Improving the Cancer Journey

3
‘Improving the Cancer Journey’ (ICJ) was commissioned in 2014 in Glasgow, Scotland. It is the first community-based cancer service of its kind in the UK and is unique for three interrelated reasons. First, stakeholders are multi-professional. Led by the city council with partners across health, social care, housing and the third sector. Second, the key intervention (Holistic Needs Assessment (HNA) figure 1) is proactive: people newly diagnosed with cancer are actively sought out and referred to support. Third, the intervention is coordinated by non-clinical ‘link officers’ rather than health professionals (table 1).

Table 1 The link officer

In more detail, ICJ writes to every person with a confirmed cancer diagnosis in Glasgow and invites them to access the support, if they wish. At a pre-arranged appointment the link officer meets with their client at a location of their choice. This may be their home, a community venue such as a library or their local hospital (both inpatient and outpatient). During this appointment a HNA (figure 1) is carried out, whereby clients are asked to score each of their identified concerns from zero to 10, reflecting the severity of the concern for that person. Based on mutually agreed priorities between the patient and link officer, a care-plan is then co-constructed which details any actions that will be carried out to support the identified concerns. For example, the link officer may provide written information or make a referral to an appropriate agency. The link officer revisits each case; the timing dependant on the clients’ circumstances, severity of concerns raised, care plan details and prognosis. At this review, a second HNA is carried out to identify if the client’s concerns have reduced and/or there are any new concerns. This process continues until the client and the link officer are satisfied that no further support is required.

The service has supported approximately 4000 people since 2014 across a range of cancer types and stages and sociodemographic backgrounds [9]. However, the most common use of the service is from individuals with lung cancer, who are aged between 55-64 years and who live in areas of high deprivation, as measured by the Scottish Index of Multiple Deprivation (SIMD). Thirty per cent of ICJ clients were receiving treatment at the time of their first HNA. Most (over 50%) have at least one co-morbidity. The top three concerns for all users of ICJ are financial, fatigue and worry/anxiety. Actions taken by the service include referral to organisations for financial support (including payment of state benefits), referral to other charities for services such as counselling and complementary therapies and referral to social care for assistance with daily living.

There is quantitative and qualitative evidence that this service generates positive outcomes for individuals [9, 10]. Demonstrating a national commitment to this model of care in 2019, Macmillan Cancer Support (a UK charity) and the Scottish Government each pledged £9 million to ensure everyone diagnosed with cancer has a dedicated support worker. According to the Scottish Government [11] this will make Scotland the first country in the UK to offer cancer patients guaranteed emotional, practical and financial advice.

However, despite this public support it remains unclear what, if any, relationship there is between identifying and meeting someone’s personally identified needs and any subsequent impact on self-reported health status. This is important as it would provide currently lacking evidence of effectiveness using standardised measures. In turn, this will improve the ability to generalise findings to other geographical and cancer care settings and lay the foundation for future research to develop a conceptual theory on the relationship between ‘need’ (which may cover a number of domains) and health related quality of life [12].
Aim

The overarching aim was to analyse the impact of ICJ on self-reported health status using the EQ-5D - 3L utility measure and visual analogue scale (VAS) [13]. Secondary aim was to explore the relationships between change in health status and cancer type, cancer stage, number of HNA concerns expressed, severity of concerns and change in severity of concerns between pre and post intervention.

Hypotheses

Primary:

1. There will be a statistically significant difference between EQ-5D scores at baseline and EQ-5D scores post intervention.

Secondary:

2. There will be a relationship between changes in health status and: cancer type, cancer stage, number of concerns expressed and change in severity of concerns pre and post intervention.

Method

Design

Prospective observational cohort study.

Analytic variables

Sociodemographic data included age range, sex, and Scottish Index of Multiple Deprivation (SIMD). These data were collected with consent from the participants who had accessed the intervention at baseline. The following data were collected at baseline and also post intervention: cancer type, cancer stage, and data relating to the HNA process (figure 1) including number and mean severity rating of concerns identified. To measure self-reported health status, participants completed the EQ-5D-3L and Visual Analogue Scale (VAS) at baseline and post intervention. A utility score was computed from the EQ-5D ratings using an algorithm and value sets produced in a UK population study [14] of societal preferences using the Time Trade-off (TTO) method. A utility score of 1 is interpreted as the best possible health, 0 as death, and values of <0 as being worse than death.

Participants

In 2018/19 a consecutive, convenience sample of 437 ICJ clients completed the EQ-5D-3L and VAS on paper versions during their initial visit and again at their follow-up review. Initial assessments were face to face so individuals completed the surveys themselves. Reviews usually occurred over the telephone so the link officer, through conversation, completed it on the participants’ behalf.

Analytic plan

All data were imported into R (version 3.5.0, using ‘tidyverse’ package version 1.3.0 [15]) and SPSS package for statistics version 23, cleaned and checked for outliers. For the main hypothesis, a paired t-test was run to ascertain the difference in EQ-5D-3L scores between initial visit and post intervention, and the same for the VAS.
For the secondary aim, EQ-5D-3L and VAS change scores post intervention were tested for associations using univariate linear regressions with sociodemographic, clinical and HNA-related variables, with those found associated entered into two multiple linear regression models to identify likely predictors of change in EQ-5D scores and VAS between assessments. For descriptive statistics, means and confidence intervals were computed for approximately normally distributed variables, proportions for categorical variables, and median and minima and maxima for non-normally distributed variables. Only pairwise complete observations were used in analysis.

Regarding interpretation, the concept of ‘minimally important clinical difference’ (MICD) has been used to explain the amount of change required in a particular test score that represents a clinically meaningful change for the individual taking that test. For example, it has been used to interpret change in measures of asthma control [16] and wellbeing [17], including the EQ5D [18], and so this concept was also applied here.

**Results**

HNA data and EQ-5D results at baseline and follow-up were obtained for 349 individuals as not every client opts to have a HNA or has a Review (as of August 2019, approximately 6800 clients were referred to IC, with approx. 4100 or 60% of referrals completing a HNA, and approx. 1800 or 43% of HNAs also receiving a follow-up HNA). As detailed in Figure 2, twelve participants were excluded for not having had any concerns recorded at HNA or review, four participants were removed for having baseline and follow-up scores recorded less than 14 days apart, one participant was removed for reporting an unusually large number of concerns in their HNA, and one participant was removed for having an incomplete EQ5D. A total of 331 individuals were analysed. The time between assessments ranged from 14 to 456 days, averaging 117 days (median 84). Between baseline and follow up, self reported severity of concern dropped, in line with previous findings [9]. Figure 3 shows the mean change in the different domains of the HNA. There is further detail in supplementary file 1.

Figure 3 Baseline, Follow-up and Change score for Mean concern severity across domains. Error bars depict 95% CI. The negative change scores correspond to an improvement.

Table 2 shows patient characteristics. In summary, the majority of participants were aged between 50-64 years, 59% were female, most resided in areas of high deprivation and cancer type and stage were varied. The variable ‘Palliative care’ denotes individuals who identified as receiving palliative care at baseline or follow-up.

**Table 2. Patient characteristics**

**Primary Hypothesis**

1. There will be a statistically significant difference between EQ-5D scores at baseline and EQ-5D scores post intervention.

Table 3 presents the descriptives of the EQ-5D-3L Utility score and Visual Analogues Scale (VAS) at baseline and
follow-up. Figure 4 shows the same data but for each individual participant in spaghetti plots. Both EQ-5D measures increased, indicating an improvement in health status. The distributions of change scores for EQ-5D utility scores and VAS were approximately normal with heavier tails on the positive side, and a large proportion of 0 values. However, because the sample size was sufficiently large, the t-test was assumed to be sufficiently robust to non-normality (Lund & Lund, 2019).

Table 3. Descriptive summary of outcomes. The negative difference in concern severity is interpreted as an improvement.

Using a paired t-test, the increase in EQ-5D utility scores of 0.121 [0.0891-0.153] at follow-up was found to be statistically significant (p<.001), as was the increase in VAS of 7.81 [5.88-9.74] (p<.001). Cohen’s d effect sizes were 0.43 [0.27-0.58] for Utility score difference, and 0.42 [0.27-0.58] for VAS, both of which are considered small to moderate. The hypothesis of a significant difference between baseline and follow-up on EQ-5D scores was supported. The mean changes in EQ-5D scores fell within previously published Minimal Clinically Important Difference (MCID) estimates for oncological patients: 0.07 to 0.12 for utility scores[20], and 7 to 12 for VAS [21]. Table 4 shows the estimated proportion of individuals who had a clinically important improvement or decline using the reported MCID values as lower and upper bounds.

Table 4. Proportion of individuals whose EQ5D scores improved or declined above the MCID threshold, using published lower and upper bound estimates.

Figure 4. Spaghetti plots showing change of EQ5D Utility scores and VAS from baseline to follow-up for each participant. Each partly transparent line segment denotes one participant, with darker lines indicating overlapping trajectories. The follow-up score is marked with a circle for clarity.

Secondary hypothesis

2. There will be a relationship between changes in self-reported health related quality of life and: cancer type, cancer stage, number of concerns expressed, and change in severity of concerns pre and post intervention.

Univariate regressions of EQ-5D scores on age group, gender, cancer type, cancer stage, palliative care, deprivation level, number of concerns reported, follow-up time, and mean change in concerns between assessments can be found in Table 5. Variables that were statistically significantly (p < .05) associated with EQ-5D scores were entered into multiple regression models (Table 6). The variables used were: time elapsed between EQ-5D assessments, mean change in concerns between assessments, and palliative care, with the EQ-5D utility score model also using number of concerns as predictor. Utility score differences were only significantly different between 25-49 years, and 75 years and over, so Age was not included in the multiple regression.

Table 5. Univariate regressions of patient characteristics and outcomes on EQ-5D scores; p-values significant at α<.05 shown in bold. Follow-up time in multiples of 30 day increments was defined as the number of days divided by 30 to approximate number of months.

Both the EQ-5D utility score and VAS models were heteroscedastic so White’s heteroscedasticity-consistent standard errors were used (HC0, using R ‘sandwich’ package version 2.5-1) [22][23]. Following assumption
testing [19], the omnibus test of the EQ-5D utility score model was significant at $F(4,271) = 13.9$, $p < .001$, adj. $R^2 = .158$, with regression terms \textit{Mean change in concern severity between assessments} significant at $p < .001$, \textit{Palliative care} significant at $p < .01$, and \textit{Number of concerns} significant at $p < .05$. \textit{Time elapsed between assessments} was not a significant predictor. The omnibus test of the VAS score model was significant at $F(3,272) = 8.6$, $p < .001$, adj. $R^2 = .076$, with regression terms \textit{Time elapsed between assessments}, \textit{Mean change in concern severity between assessments} significant at $p<.001$, and \textit{Palliative care} statistically significant at $p < .0001$. Regression coefficients, robust standard errors and confidence intervals for both models can be found in Table 5.

HNA average score decreased, indicating a reduction in severity of concerns (figure 3). The mean concern severity was 6.47 [6.23-6.71] at baseline, dropping to 2.90 [2.66-3.13] post intervention. Only three individuals (<1%) showed increase in severity of concern post intervention. Mean concern severity was independent of the number of concerns (Spearman’s $\rho=.076$, $p=.17$). In the EQ-5D utility score change model, the strongest predictor was \textit{Mean concern change} ($\beta=-0.34$), meaning that a one standard deviation (1SD) decrease in concern severity at follow-up corresponded to a 0.34SD increase in utility score. Next strongest predictor was \textit{Palliative care}, which contributed -0.408SD to the EQ-5D utility score change. Finally, when the \textit{number of concerns} increased by 1SD, the utility score increased by 0.13SD. The time elapsed between EQ-5D assessments was not a significant predictor in the model.

In the VAS model, the strongest predictor was \textit{Palliative care}, which contributed approximately -8 points on the VAS scale, followed by \textit{Mean concern change}, where a 1SD decrease in concerns corresponded to a 0.17SD increase in VAS. \textit{Time elapsed between assessments} was a significant predictor of VAS change in the model, corresponding to a 0.16SD increase in VAS in a 1SD time increase.

Table 6. Linear multiple regression with White’s heteroscedasticity-consistent standard errors for Utility score change and VAS change at follow-up; $p$-values significant at $\alpha<.05$ shown in bold

\begin{table}
\centering
\begin{tabular}{|c|c|}
\hline
\textbf{Predictor} & \textbf{Coefficient} \\
\hline
\textit{Mean concern change} & \(-0.34\) \\
\textit{Palliative care} & \(-0.408\) \\
\textit{Number of concerns} & \(0.13\) \\
\textit{Time elapsed between assessments} & \(0.16\) \\
\hline
\end{tabular}
\caption{Linear multiple regression with White’s heteroscedasticity-consistent standard errors for Utility score change and VAS change at follow-up}
\end{table}

\textbf{Discussion}

This study has described a significant association between change in HNA score and self-reported health status. Following intervention from ICJ, mean HNA concern severity reduced from 6.4 [6.23-6.71] to 2.9 [2.66-3.13], consistent with the decrease seen in the wider ICJ population [9]. Concurrently, EQ-5D score increased from 0.45 [0.422-0.488] to 0.57 [0.547-0.604], while VAS scores increased from 49 [47.1-51.1] to 57 [54.9-58.9]. This EQ-5D utility score difference of 0.12 [0.0891-0.153] and VAS difference of 7.81 [5.88-9.74] are considered to be above the ‘minimally important clinical difference’ (MICD) in EQ-5D scores described by Coretti et al., [20], and Pickard et al [24]. In other words, this level of improvement has been described as an important and meaningful improvement for patients [25]. This is also consistent with qualitative evidence [10] on the perceived benefits of using ICJ.

To further contextualise the scores in this study, Supplementary file 2 presents mean baseline and post intervention EQ-5D utility scores from participants in this study, according to cancer type. The same table also contains a reference range of the highest and lowest mean EQ-5D utility scores for the same cancer types, obtained from international studies specifically designed to ascertain EQ-5D population norms. These values show that the ICJ cohort recorded some of the lowest quality of life scores published in the cancer literature. The
intervention is therefore not just clinically meaningful but also successfully reaching the population that requires it the most.

Overall, the models explained a moderate to small amount of variance (approximately 16% for utility scores, and 8% for VAS). The strongest predictor was ‘mean concern change’. Over the same period of time that the EQ-5D scores increased, the HNA mean level of concern severity decreased. Receiving palliative care and the number of concerns were also significant predictors, along with time between assessments on the VAS scores, but not the index scores. However, a proportion of the improvement remains unexplained. There is a missing explanatory variable, consistent with the interpretation that the process of ICJ is also contributing to the change in health status. For example, identifying a larger number of concerns at baseline was associated with increased health status at follow up. This also points to the process of ICJ being a determinant of improvement: identifying more concerns leads to more engagement with the services on offer, resulting in better outcomes. However, this remains unknown at present because there is no measure of impact of specific services. This hypothesis will be explored in future research by recording attendance and satisfaction ratings of all the services provided and signposted by ICJ.

Previous research investigating the association between needs assessment and improved outcomes has predominantly focused on measuring impact through a range of measurable outcomes such as distress, anxiety, depression and pain using specific tools such as the Distress Thermometer (DT) [26–28]. Qualitative evidence on the use of HNA has shown that it can improve communication between patients and clinicians, providing an opportunity to discuss non-clinical concerns and signpost patients to a variety of different services [29, 30]. However, assessment alone does not always lead to improved outcomes. Sandsund et al., [29] did not find a statistically significant difference in quality of life after using the HNA in 124 women diagnosed with gynaecological cancer. Hollingworth et al. [31] found no evidence of an effect on distress or quality of life, and concluded that the timing of the assessment and the profession of the assessor can impact on outcomes.

The HNA assessor in ICJ was a non-clinical expert. Link officers come to this role with backgrounds in financial inclusion and city council processes, and then undertake a three-month training programme to become specialists. They are therefore equipped with a range of skills and knowledge to help navigate people affected by cancer through the complex systems within health but especially through social care and the third sector. In other studies only limited training was provided to the assessors [7]. This is likely to impact on the quality of the HNA interaction and the knowledge and confidence required to make referrals across different services and sectors. Further, it is rational to suggest that people tailor responses to what they perceive to be the expertise of the person conducting the consultation [32]. Accordingly, in this study participants commonly identified non-clinical concerns such as finances and worry/anxiety. These concerns have been identified as being a substantial burden with individuals much more likely to rate their physical health, mental health, and satisfaction with social activities and relationships as poor compared to those with no financial hardship [33]. For that reason, relieving financial burden is likely to have had a substantially positive impact on other areas of concern, which may also add to the interpretation of the findings in this study.

Identifying and assessing individual concerns [34–36] is unarguably beneficial as it can help, amongst other things, with resource allocation. However, to our knowledge, this is the first study to quantify what this means to individuals’ health related quality of life. This is important because while quality of life has multiple determinants this study has reported that it is possible to capture a meaningful improvement in quality of life as a function of reducing someone’s personally identified concerns.
Strengths and limitations

The current study has several strengths. This is the first examination of health status over time in a large and heterogeneous sample of cancer patients who have all been supported through the HNA process. The primary limitation is that the sample was not random, and the time between EQ-5D assessments was not standardized. Some degree of improvement over time was anticipated. The way ICJ functions is that assessments are followed by referrals and then followed by further ICJ contact. Therefore, over this time period it is likely that individuals may, for example, finish their treatment and report a higher health status. However, the time elapsed between assessments was only a significant predictor of improvement in VAS but not utility scores. Nevertheless, as stated, most of the improvement was unexplained. While a broad array of variables were considered for the model we acknowledge that other variables may have influenced the findings. For example, information on comorbidities and more detailed information on participant’s use of other services and interactions with other professionals would have been beneficial. Future research should identify a broader array of variables including sociodemographic, interpersonal (patient and assessor interaction) and clinical to explore the relationship between needs assessment and health related outcomes.

Conclusions

The primary aim of this research was to document any changes in self-reported health status following intervention from a cancer service. Health status significantly increased following intervention from ICJ. This is noteworthy because at a time where the cancer workforce is stretched and patient numbers are increasing there is an urgent need to rethink how to use resources efficiently without negatively impacting on patient care. The fact that the assessors in this study were non-health based could well be a model to follow - primarily due to their expertise and the types of concerns they tended to elicit and manage. This sample had complex needs with a large proportion residing in areas of high deprivation, with a poor cancer prognosis and with baseline levels of health status that were considerably lower than other cancer populations. That they can be helped in a clinically meaningful way bodes well for those needing similarly targeted support in the future. These results encourage wide application of HNA and supportive care planning combined with approaches like ICJ that tailor support based on need.

Abbreviations

Holistic Needs Assessment (HNA)
Improving the Cancer Journey (ICJ)
EQ-5D (EuroQol 5 Dimension)
VAS (Visual Analogue Scale)

Declarations

Ethics approval and consent to participate

The study was reviewed and approved by the West of Scotland Research Ethics Committee (WS/15/0166) and Edinburgh Napier University School of Health and Social Care Ethics Committee.

Consent for publication

Informed consent was obtained from all participants

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests

**Funding**

This study is funded by Macmillan Cancer Support, UK. The funders had no role in the conception of the study design. They provided comment on data collection, analysis and interpretation.

**Authors contributions**

AS conceived the study design, wrote the manuscript and oversees all aspects of the study. JY conceived the study design, wrote the manuscript and contributed to the analysis. JS wrote the manuscript and carried out data analysis. All authors have read and approved the manuscript.

**Acknowledgements**

Not applicable

**References**

1. Jefford M, Ward AC, Lisy K, Lacey K, Emery JD, Glaser AW, Cross H, Krishnasamy M, McLachlan SA, Bishop J: *Patient-reported outcomes in cancer survivors: a population-wide cross-sectional study*. Support Care Cancer 2017, 25:3171-3179.
2. Thomas H, Mitchell G, Rich J, Best M: *Definition of whole person care in general practice in the English language literature: A systematic review*. BMJ Open 2018, 8:023758.
3. Johnston L, Young J, Campbell K: *The implementation and impact of Holistic Needs Assessments for people affected by cancer: A systematic review and thematic synthesis of the literature*. Eur J Cancer Care (Engl) 2019:13087.
4. Skrabal Ross X, Gunn KM, Olver I, Willems RA, Lechner L, Mesters I, Bolman CAW: *Online psychosocial interventions for posttreatment cancer survivors: An international evidence review and update*. Curr Opin Support Palliat Care 2020:40–50.
5. Snowden A, Young J: *When are Holistic Needs not Holistic Needs?* In RCN Int Nurs Res Conf Exhib 2017. Oxford: RCN; 2017:http://docplayer.net/60685154-Conference-brochure-.
6. The Scottish Government: *Beating Cancer. Ambition and Action*. Edinburgh; 2016.
7. Bidstrup PE, Johansen C, Mitchell AJ: *Screening for cancer-related distress: Summary of evidence from tools to programmes*. Acta Oncol (Madr) 2011:194–204.
8. Senf B, Fettel J, Demmerle C, Maiwurm P: *Physicians’ attitudes towards psycho-oncology, perceived barriers, and psychosocial competencies: Indicators of successful implementation of adjunctive psycho-oncological care?* Psychooncology 2019, 28:415–422.
9. Snowden A, Young J, Savinc J: *Proactive Community Support tailored to Holistic Needs: a Cohort Study*. Cancer Med 2018, 00:1709.
10. Young J, Snowden A: *A qualitative study on the perceived impact of using an integrated community - based supportive cancer service*. Eur J Cancer Care 2019(January):1-9.
11. The Scottish Government: *£18 million funding for cancer support workers* [https://www.gov.scot/news/18-million-funding-for-cancer-support-workers-1/]
12. Asadi-Lari M, Tamburini M, Gray D: *Patients’ needs, satisfaction, and health related quality of life: towards a comprehensive model*. Health Qual Life Outcomes 2004, 2:2–32.
13. Jang RW, Isogai PK, Mittmann N, Bradbury PA, Shepherd FA, Feld R, Leighl NB: *Derivation of utility values from European organization for research and treatment of cancer quality of life-core 30 questionnaire values in lung cancer*. J Thorac Oncol 2010, 5:1953–1957.
14. Szende A, Oppe M, de Charro F: Comparative review of Time Trade-Off value sets. In EQ-5D Value Sets; 2007:21-28.

15. Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Pedersen T, Miller E, Bache S, Müller K, Ooms J, Robinson D, Seidel D, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H: Welcome to the Tidyverse. J Open Source Softw 2019, 4:1686.

16. Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P: The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009, 124:719–23.

17. Björner JB, Wallenstein G V., Martin MC, Lin P, Blaisdell-Gross B, Piech CT, Mody SH: Interpreting score differences in the SF-36 Vitality scale: Using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin 2007, 23:731–739.

18. Johnsen LG, Hellum C, Nygaard ØP, Storheim K, Brox JI, Rossvoll I, Leivseth G, Grotle M: Comparison of the SF6D, the EQ5D, and the Oswestry disability index in patients with chronic low back pain and degenerative disc disease. BMC Musculoskelet Disord 2013, 14.

19. Lund, M., Lund A: Transformations in SPSS. 2019.

20. Coretti S, Ruggeri M, McNamee P: The minimum clinically important difference for EQ-5D index: A critical review. Expert Rev Pharmacoeconomics Outcomes Res 2014:221-233.

21. Simon AS, Neary MP, Cella D: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007, 5.

22. Solli O, Stavem K, Kristiansen IS: Health-related quality of life in diabetes: The associations of complications with EQ-5D scores. Health Qual Life Outcomes 2010, 8:1-8.

23. Zeileis A: Econometric computing with HC and HAC covariance matrix estimators. J Stat Softw 2004, 11:1-17.

24. Pickard AS, Wilke C, Lin H, Lloyd A: Impact of Cancer on Health Related Quality of Life: Evidence Using the Eq-5D. Coll Pharm Univ Illinois Chicago Chicago 2006:371-411 http://epiclin.org/wpress/euroqol/wp-conte.

25. McGlothlin AE, Lewis RJ: Minimal clinically important difference: Defining what really matters to patients. JAMA - J Am Med Assoc 2014:1342-1343.

26. Carlson LE, Waller A, Groff SL, Bultz BD: Screening for distress, the sixth vital sign, in lung cancer patients: Effects on pain, fatigue, and common problems - Secondary outcomes of a randomized controlled trial. Psychooncology 2013, 22:1880-1888.

27. Carlson LE, Groff SL, Maciejewski O, Bultz BD: Screening for distress in lung and breast cancer outpatients: A randomized controlled trial. J Clin Oncol 2010.

28. Diplock BD, McGarragle KMC, Mueller WA, Haddad S, Ehrlich R, Yoon DHA, Cao X, Al-Allaq Y, Karanicolas P, Fitch MI, Myers J, Mitchell AJ, Ellis JW: The impact of automated screening with Edmonton Symptom Assessment System (ESAS) on health-related quality of life, supportive care needs, and patient satisfaction with care in 268 ambulatory cancer patients. Support Care Cancer 2019, 27:209-218.

29. Sandsund C, Towers R, Thomas K, Tigue R, Lalji A, Fernandes A, Doyle N, Jordan J, Gage H, Shaw C: Holistic needs assessment and care plans for women with gynaecological cancer: Do they improve cancer-specific health-related quality of life? A randomised controlled trial using mixed methods. BMJ Support Palliat Care 2017, Online Fir(28 August 2017):001207.

30. Ristevski E, Regan M, Jones R, Breen S, Batson A, Mcgrail MR: Cancer patient and clinician acceptability and feasibility of a supportive care screening and referral process. Heal Expect 2015, 18:406–418.

31. Hollingworth W, Metcalfe C, Mancero S, Harris S, Campbell R, Biddle L, McKell-Redwood D, Brennan J: Are needs assessments cost effective in reducing distress among patients with cancer? A randomized controlled trial using the distress thermometer and problem list. J Clin Oncol 2013, 31:3631-3638.

32. Snowden A: Is Understanding an Intervention? In Br Psycholgical Soc Heal Qual Outcomes. Bristol: SIGOPAC; 2016.

33. Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Puszta1 L, Sanft T, Hofstatter EW, Killelea BK, Knobf MT, Lannin DR, Abu-Khalaf M, Horowitz NR, Chagpar AB: Impact of Financial Burden of Cancer on Survivors’ Quality of Life. J Oncol Pract 2014, 10:332–338.
Tables

Table 1

The link officer

ICJ link officers are city council employees, not health care professionals. The council currently employ seven link officers. When first join the service, link-officers have a 3-month induction period where each officer becomes familiar with their role and core of a range of training. Currently all officers are, or are working towards, being accredited with a Level 3 Scottish Vocational Qualification (SVQ) in healthcare support to reflect their competencies in this area. Level 3 SVQ is a vocational qualification academically equivalent to graduate diploma level, or second year of baccalaureate degree.

Table 2

| Characteristic            | Statistic | N   |
|---------------------------|-----------|-----|
| Age, N (%)                |           | 330 |
| 25 to 49 years            | 32 (9.70%)|     |
| 50 to 64 years            | 127 (38.5%)|    |
| 65 to 74 years            | 112 (33.9%)|   |
| 75 years and over         | 59 (17.9%) |    |
| Sex, N (%)                |           | 325 |
| Female                    | 192 (59.1%)|    |
| Male                      | 133 (40.9%)|    |
| Cancer type, N (%)        |           | 331 |
| Bowel                     | 29 (8.76%)  |    |
| Cancer stage at baseline, N (%) | 273 |
|-------------------------------|-----|
| Living with condition         | 55 (20.1%) |
| Receiving palliative care     | 26 (9.52%) |
| Recently completed treatment (within 1 month) | 17 (6.23%) |
| Recently diagnosed (1 month)  | 35 (12.8%) |
| Undergoing tests              | 18 (6.59%) |
| Undergoing treatment          | 122 (44.7%) |

| Cancer stage at follow-up, N (%) | 322 |
|---------------------------------|-----|
| Living with condition           | 144 (44.7%) |
| Receiving palliative care       | 55 (17.1%) |
| Recently completed treatment (within 1 month) | 28 (8.70%) |
| Recently diagnosed (1 month)    | 1 (0.31%) |
| Recurrence                      | 1 (0.31%) |
| Undergoing tests                | 9 (2.80%) |
| Undergoing treatment            | 84 (26.1%) |

| Palliative care, N (%) | 276 |
|------------------------|-----|
| Yes                    | 59 (21.4%) |
| No                     | 217 (78.6%) |

| Deprivation (1=most deprived), Median [min-max] | 31 [1-20] | 331 |

Table 3
| Measure          | Declined          | Improved          |
|------------------|-------------------|-------------------|
| Utility score    | 12.7 - 17.5%      | 41.7 - 48.6%      |
| VAS              | 6.3 - 13.6%       | 30.5 - 48.0%      |

Table 4

| Outcome                                           | Mean [95% CI]       |
|---------------------------------------------------|---------------------|
| Follow-up time (days)                             | 117 [107;126]       |
| Concern severity at baseline                      | 6.47 [6.23;6.71]    |
| Concern severity at follow-up                     | 2.90 [2.66;3.13]    |
| Concern severity difference at follow-up          | -3.57 [-3.84;-3.30] |
| VAS at baseline                                   | 49.1 [47.1;51.1]    |
| VAS at follow-up                                  | 56.9 [54.9;58.9]    |
| VAS difference at follow-up                       | 7.81 [5.88;9.74]    |
| Utility score at baseline                         | 0.45 [0.42;0.49]    |
| Utility score at follow-up                        | 0.58 [0.55;0.60]    |
| Utility score difference at follow-up             | 0.12 [0.09;0.15]    |

Table 5

| Variable | N   | Utility score | Beta | 95% CI  | p-value | VAS | Beta | 95% CI  | p-value |
|----------|-----|---------------|------|---------|---------|-----|------|---------|---------|
| Age      | 330 |               |      |         |         |     |      |         |         |
| 25 to 49 years |     |               |      |         |         |     |      |         |         |
| Age Group                               | 50 to 64 years | 65 to 74 years | 75 years and over | Sex | 325 |
|----------------------------------------|----------------|----------------|-------------------|-----|-----|
| **Female**                             |                |                |                   |     |     |
| **Male**                               | 0.01           | -0.05, 0.08    | 0.7               | 0.33| -3.6, 4.2 | 0.9 |
| **Cancer type**                        |                |                |                   |     |     |
| **Bowel**                              |                |                |                   |     |     |
| **Breast**                             | 0              | -0.13, 0.12    | >0.9              | -0.99| -8.7, 6.8 | 0.8 |
| **Lung**                               | -0.02          | -0.15, 0.11    | 0.7               | -3.5| -11, 4.2 | 0.4 |
| **Other**                              | 0.03           | -0.08, 0.15    | 0.6               | 0.07| -7.1, 7.3 | >0.9 |
| **Prostate**                           | 0.08           | -0.07, 0.23    | 0.3               | 1.6 | -7.7, 11 | 0.7 |
| **Cancer stage at baseline**           |                |                |                   |     | 273 |
| **Living with condition**              |                |                |                   |     |     |
| **Receiving palliative care**          | -0.08          | -0.21, 0.06    | 0.3               | -3.3| -11, 4.9 | 0.4 |
| **Recently completed treatment (within 1 month)** | 0.04          | -0.12, 0.19    | 0.7               | 1.3 | -8.2, 11 | 0.8 |
| **Recently diagnosed (1 month)**       | 0.08           | -0.04, 0.20    | 0.2               | -0.32| -7.7, 7.0 | >0.9 |
|                                |     |     |     |     |     |     |
|--------------------------------|-----|-----|-----|-----|-----|-----|
| **Undergoing tests**           | 0.21| 0.05,0.36 | 0.008 | 0.76 | -8.5, 10 | 0.9 |
| **Undergoing treatment**       | 0.06| -0.04,0.15 | 0.2   | 3    | -2.6, 8.5 | 0.3 |
| **Cancer stage at follow-up**  | 322 |     |     |     |     |     |
| **Receiving palliative care**  | -0.08| -0.18,0.01 | 0.075 | -9   | -15, -3.5 | 0.001 |
| **Recently completed treatment (within 1 month)** | -0.03| -0.15,0.09 | 0.6   | 2.2  | -4.9, 9.4 | 0.5 |
| **Recently diagnosed (1 month)** | -0.13| -0.72,0.45 | 0.6   | -9.9 | -45, 25   | 0.6 |
| **Recurrence**                 | 0.45| -0.13,1.0   | 0.13  | -4.9 | -40, 30   | 0.8 |
| **Undergoing tests**           | 0.05| -0.15,0.25  | 0.6   | -11  | -23, 1.2  | 0.077 |
| **Undergoing treatment**       | -0.01| -0.09,0.07  | 0.8   | -2.8 | -7.5, 2.0 | 0.3 |
| **Palliative care**            | 276 |     |     |     |     |     |
| **Yes**                        |     |     |     |     |     |     |
| **No**                         | 0.09| 0.01,0.18   | 0.029 | 6.6  | 1.7, 12   | 0.008 |
| **Deprivation (1=most deprived)** | 331 | 0    | -0.01,0.00 | 0.2  | 0.06 | -0.34, 0.45 | 0.8 |
| **Number of**                  |     |     |     |     |     |     |
|                               | 0.00, |     |     |     | -0.37, |     |
### Table 6

| Predictors                                     | EQ5D-3L Utility value change | EQ5D VAS change |
|------------------------------------------------|------------------------------|-----------------|
|                                                 | Estimates std. Beta CI       | Estimates std. Beta CI |
| Intercept                                       | -0.109 (-0.195 to -0.022)    | -0.109 (-3.370 to 4.287) |
| Time elapsed (30 day increment)                 | 0.012 (0.007 to 0.030)       | 0.012 (0.207 to 1.076) |
| Mean concern change                             | -0.04 (-0.055 to -0.024)     | -0.04 (-1.132 to -0.166) |
| Number of concerns at baseline                  | 0.016 (0.001 to 0.032)       | 0.016 (0.007 to -0.863) |
| Palliative care                                 | -0.12 (-0.206 to -0.033)     | -0.12 (-14.178 to -3.095) |
| Observations                                    | 276                          | 276             |
| R² / R² adjusted                                 | 0.170 / 0.158                | 0.087 / 0.077   |
Living with and beyond cancer – identifying your concerns

Completed by: ____________________________
Date: ____________________________
Designation: ____________________________
Contact details: ____________________________

This self assessment is optional, however it will help us understand the concerns and feelings you have. It will also help us identify any information and support you may need in the future.

If any of the problems below have caused you concern in the past week and if you wish to discuss them with a healthcare professional, please tick the box. Leave the box blank if it doesn't apply to you or you don't want to discuss it now.

☐ I have questions about my diagnosis/treatment that I would like to discuss.

Physical concerns
☐ Breathing difficulties
☐ Passing urine
☐ Constipation
☐ Diarrhoea
☐ Eating or appetite
☐ Indigestion
☐ Sore or dry mouth
☐ Nausea or vomiting
☐ Sleep problems/nightmares
☐ Tired/exhausted or fatigued
☐ Swollen tummy or limb
☐ High temperature or fever
☐ Getting around (walking)
☐ Tingling in hands/feet
☐ Pain
☐ Hot flushes/sweating
☐ Dry, itchy or sore skin
☐ Wound care after surgery
☐ Memory or concentration
☐ Taste/sight/hearing
☐ Speech problems
☐ My appearance
☐ Sexuality

Practical concerns
☐ Caring responsibilities
☐ Work and education
☐ Money or housing
☐ Insurance and travel
☐ Transport or parking
☐ Contact/communication with NHS staff
☐ Housework or shopping
☐ Washing and dressing
☐ Preparing meals/drinks

Family/relationship concerns
☐ Partner
☐ Children
☐ Other relatives/friends

Emotional concerns
☐ Difficulty making plans
☐ Loss of interest/activities
☐ Unable to express feelings
☐ Anger or frustration
☐ Guilt
☐ Hopelessness
☐ Loneliness or isolation
☐ Sadness or depression
☐ Worry, fear or anxiety

Spiritual or religious concerns
☐ Loss of faith or other spiritual concern
☐ Loss of meaning or purpose of life
☐ Not being at peace with or feeling regret about the past

Lifestyle or information needs
☐ Support groups
☐ Complementary therapies
☐ Diet and nutrition
☐ Exercise and activity
☐ Smoking
☐ Alcohol or drugs
☐ Sun protection
☐ Hobbies
☐ Other

Please mark the scale to show the overall level of concern you've felt over the past week. You may also wish to score the concerns you have ticked from 1 to 10.

1 2 3 4 5 6 7 8 9 10

WE ARE MACMILLAN CANCER SUPPORT

NHS Department of Health

NHS Improvement

This document is copyright © 2012, Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of Man (604). MAC13689

Figure 1
Sample inclusions and exclusions.
Figure 3

Baseline, Follow-up and Change score for Mean concern severity across domains. Error bars depict 95% CI. The negative change scores correspond to an improvement.
Figure 4

Spaghetti plots showing change of EQ5D Utility scores and VAS from baseline to follow-up for each participant. Each partly transparent line segment denotes one participant, with darker lines indicating overlapping trajectories. The follow-up score is marked with a circle for clarity.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementaryfile1Changeinconcerns290420v2.docx
- Supplementaryfile2v2.docx
- SummaryofEQ5Dstudiessupplementary.docx